ABSTRACT
Background High rates of breakthrough rotavirus gastroenteritis have been reported among Aboriginal children living in rural and remote Australia despite receipt of two doses of oral rotavirus vaccine. Histo-blood group antigens (HBGAs) may mediate rotavirus genotype-dependent differences in susceptibility to rotavirus infection and immune responses to rotavirus vaccination.
Methods HBGA phenotype – Lewis and secretor status - was determined by enzyme immunoassay of saliva samples obtained from Australian Aboriginal children who were enrolled at age 6 to <12 months in a randomised clinical trial of an additional (booster) dose of oral rotavirus vaccine. Participants had received the routine two-dose schedule of oral rotavirus vaccine administered at age 6 weeks and 4 months. Non-secretor phenotype was confirmed by DNA extraction to identify FUT2 ‘G428A’ mutation. Rotavirus seropositivity was defined as serum anti-rotavirus IgA ≥ 20 AU/mL measured by ELISA on enrolment.
Results Of 156 children, 119 (76%) were secretors, 129 (83%) were Lewis antigen positive, and 105 (67%) were rotavirus IgA seropositive. Eighty-seven of 119 (73%) secretors were rotavirus seropositive, versus 4/9 (44%) weak secretors and 13/27 (48%) non-secretors. Eighty-nine of 129 (69%) Lewis antigen positive children were rotavirus seropositive versus 10 of 19 (53%) of those who were Lewis antigen negative.
Conclusions Most Australian Aboriginal children were secretor and Lewis antigen positive. Non-secretor children were less likely to be seropositive for rotavirus following vaccination, but this phenotype was less common. HBGA status is unlikely to fully explain the underperformance of rotavirus vaccine at a population level among Australian Aboriginal children.
Competing Interest Statement
NAC declares that he has participated on a Data Safety Monitoring Board and/ or Advisory Board for GlaxoSmith Kline and Sanofi Pasteur who manufacture rotavirus vaccines. CD, NB, AH and JEB declare that MCRI received funding to support the development and conduct of the laboratory assays for this study. CD also declares that she is CI on a Bill & Melinda Gates Foundation Grant, Sequencing and Antigenic Cartography of Enteric Viruses (SACEV), that she has been a member of a GSK expert advisory board and received a travel award to attend the 2022 Double-stranded RNA virus meeting in Canada. JEB declares that she has received grant funding from the Australian Government Department of Health and GlaxoSmithKline for the Australian Rotavirus Surveillance Program, from the Bill and Melinda Gates Foundation for RV3BB rotavirus vaccine clinical trials, and from the World Health Organisation for support for the Global Diarrhea Surveillance Program. JEB declares that she is a member of a Data Safety Monitoring Board and/ or Advisory Board for Vakzine Projekt Management GmbH Germany. The authors declare no other competing interests.
Funding Statement
This work was supported by the National Health Medical Research Council (grant number 1086952) which had no role in study design, data collection, data analysis, data interpretation, or writing of this report. BFM is supported by a National Health and Medical Research Council Postgraduate Scholarship (grant number 1134095), a Royal Australasian College of Physicians Paediatrics & Child Health Division National Health and Medical Research Council Scholarship and a Douglas and Lola Douglas Scholarship in Medical Science, Australian Academy of Science. TS was supported by a National Health and Medical Research Council Career Development Fellowship (grant number 1111657) and a Medical Research Future Fund Investigator Grant (grant number MRF1195153). MD is supported by a Murdoch Childrens Research Institute Clinician Scientist Research Fellowship, University of Melbourne.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Human Research Ethics Committee of Northern Territory Department of Health and Menzies School of Health Research gave ethical approval for this work (2020-3759). The ORVAC protocol is registered on ClinicalTrials.gov (NCT02941107).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors